Bortezomib combined with thalidomide and dexamethasone is effective for patient with crystal-storing histiocytosis associated with monoclonal gammopathy of undermined significance

Eur J Haematol. 2012 Aug;89(2):183-4. doi: 10.1111/j.1600-0609.2012.01800.x. Epub 2012 Jun 7.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Angiogenesis Inhibitors / administration & dosage*
  • Antineoplastic Agents, Hormonal / administration & dosage*
  • Boronic Acids / administration & dosage*
  • Bortezomib
  • Dexamethasone / administration & dosage*
  • Female
  • Histiocytosis / drug therapy*
  • Histiocytosis / etiology
  • Histiocytosis / pathology
  • Humans
  • Paraproteinemias / complications
  • Paraproteinemias / drug therapy*
  • Paraproteinemias / pathology
  • Pyrazines / administration & dosage*
  • Thalidomide / administration & dosage*

Substances

  • Angiogenesis Inhibitors
  • Antineoplastic Agents, Hormonal
  • Boronic Acids
  • Pyrazines
  • Thalidomide
  • Bortezomib
  • Dexamethasone